Tenet Health(US:THC)2025-07-22 14:00Financial Performance Highlights - Consolidated Adjusted EBITDA reached $1.121 billion, exceeding the high end of the Q2 outlook [7] - Consolidated Adjusted EBITDA grew by 19% with a margin of 21.3% [8] - Adjusted diluted EPS increased by 74% [8] Segment Performance - Ambulatory Adjusted EBITDA grew by 11%, with same-facility revenue growth of 7.7% and a 39.2% Adjusted EBITDA margin; 8 facilities were added in Q2 [8] - Hospitals Adjusted EBITDA grew by 25%, with same-hospital admissions growth of 1.6% and a 15.6% Adjusted EBITDA margin [8] Financial Outlook - The company increased its FY 2025 Consolidated Adjusted EBITDA outlook by $395 million, now expecting $4.40 to $4.54 billion [9] - Net operating revenues for 2025 are projected to be between $20.95 and $21.25 billion [10] - Free cash flow for 2025 is expected to be between $2.025 and $2.275 billion [12] USPI Performance - USPI's net revenue is projected to reach $5.075 billion in 2025, reflecting a CAGR of 15.3% [16] - USPI's Adjusted EBITDA is projected to reach $2.020 billion in 2025, reflecting a CAGR of 14.5% [17] - USPI has a consistent track record of approximately 40% Adjusted EBITDA margins [18] - USPI's same-facility system-wide revenue CAGR from 2015-2025 is 6.1% [20] Capital Allocation - Q2 2025 free cash flow was $743 million [31] - The company repurchased approximately 4.6 million shares in Q2 2025 for $747 million, and 7.2 million shares YTD for $1.1 billion [32] - The Board of Directors authorized a $1.5 billion increase to the share repurchase program [32] Balance Sheet - The company has $2.6 billion cash on hand as of June 30, 2025 [31] - The company's EBITDA leverage ratio is 2.45x (3.11x EBITDA-NCI) [31]